Press Releases

Siemens Healthineers has launched a rapid and easy-to-use antigen test for the detection of SARS-CoV-2, the virus that causes COVID-19. The CLINITEST Rapid COVID-19 Antigen Test is a point-of-care cassette test that does not require laboratory instruments or specialized lab personnel to administer, and it delivers results in only 15 minutes.

Siemens Healthineers is debuting its new fluoroscopy system, the LUMINOS Lotus Max. The system offers leading technology in radiography and fluoroscopy. "With our new device, healthcare professionals benefit from a new level of integration for ‘uninterrupted flow‘ in radiographic and fluoroscopic exams," says Carsten Bertram, Head of X-ray Products.

Siemens Healthineers and Klinikum Lippe GmbH (KLG) are entering into a ten-year technology partnership for all the healthcare provider’s locations. The contract covers delivery and maintenance of large imaging equipment and ultrasound units. The partnership agreement is for a project total of about EUR 30 million.

RHÖN-KLINIKUM AG and Siemens Healthineers have signed a partnership agreement under which RHÖN-KLINIKUM Campus Bad Neustadt acquires the status of Siemens Healthineers European Center of Reference for Cardiovascular Medicine.

Siemens Healthineers has entered a collaboration agreement with Novartis Pharma AG to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline.

The collaboration will standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization that could one day be extrapolated to thresholds considered sufficient to confer immunity.

Siemens Healthineers AG has successfully placed 75 million new shares with institutional investors through an accelerated bookbuilding offering. The placement price was set at EUR 36.40 per share, resulting in gross proceeds of around EUR 2.73 billion before deduction of commissions and expenses.

Siemens Healthineers has received FDA Emergency Use Authorization (EUA) for the SARS-CoV-2 IgG (COV2G) antibody test, the first antibody test authorized with a semi-quantitative detection claim.

Siemens Healthineers AG today announced its results for the third quarter of fiscal year 2020 that ended June 30, 2020.

Today, Siemens Healthineers AG (Frankfurt: SHL) and Varian Medical Systems, Inc. (NYSE: VAR) announced that they have entered into an agreement, pursuant to which Siemens Healthineers shall acquire all shares of Varian for USD 177.50 per share in cash. This corresponds to a purchase price of approximately USD 16.4 billion.

Bayer and Siemens Healthineers present the new Imaging System Interface for magnetic resonance imaging at this year’s ECR. It is a joint development from Bayer and Siemens Healthineers and the first injector scanner interface for the MRI suite. It synchronizes the Bayer MRXperion Injection System and the Siemens Healthineers MR scanner.

SARS-CoV-2 antibody test from Siemens Healthineers evaluated against other leading antibody assays in Public Health England study distinguishing itself as the only assay tested found to meet both the sensitivity and specificity requirements set out within the MHRA’s Target Product Profile for immunoassays.

Siemens Healthineers introduces Ysio X.pree,the world's first intelligent X-ray system with integrated AI for optimizing the daily routine of image acquisition in radiography. To assist with image assessment, Siemens Healthineers also offers its new AI-Rad Companion Chest X-ray, an AI software that supports clinical decision making on thorax images.

Since the end of March, the Department of Diagnostic and Interventional Radiology at Freiburg University Hospital (UKF) has been working with Siemens Healthineers on a joint project in the field of tele-imaging.

With its teamplay myCare Companion software, the company is bringing a new and flexible telemedicine solution to the market that enables remote care for patients with chronic diseases. The teamplay myCare Companion allows healthcare providers to design their own telemedicine programs and flexibly adapt the underlying technology to their needs.